and natural killer cells. 8 LAs might also directly affect cancer cells. Na V 1.5 channels are not only expressed in the heart, they are also expressed by breast and colon cancer cells in which their activity contributes to migration and invasion. [9] [10] [11] [12] In keeping with this, inhibition of Na V 1.5 by LAs attenuates colon cancer invasion 9, 10 and xenograft studies demonstrate that VASC inhibitors reduce cancer progression in vivo. 13, 14 Intravenous administration of LAs, during surgical tumor excision, might be advantageous to optimize their putative direct beneficial effects on circulating cancer cells. 8 Lidocaine and levobupivacaine are commonly used to provide analgesia during surgical tumor excision. However, blood concentrations during their intravenous administration reach the low micromolar range well below concentrations usually examined in studies of interactions of LAs with VASCs. 15, 16 Metastatic breast and colon cancer cells predominantly express the neonatal splice variant of Na V 1.5 (nNa V 1.5), which contains amino acids encoded by exon 6a in place of those encoded by exon 6b in the aNa V 1.5 adult variant. 10, 12 Therefore, it may be advantageous to target cancer cells while sparing adult cardiac function through selectively blocking nNa V 1.5. Alternatively, preferential block of the inactivated state of Na V 1.5, which predominates in colon cancer cells due to their depolarized resting potential, 10 may provide an approach for their selective blockade by LAs.
We used the whole-cell voltage-clamp technique to evaluate the actions of micromolar concentrations of lidocaine and levobupivacaine on recombinant nNa V 1.5 and aNa V 1.5 channels expressed in HEK-293 cells. We tested the hypotheses that the LAs differentially affect (1) aNa V 1.5 and nNa V 1.5 and (2) the resting and inactivated states of these Na V 1.5 variants.
METHODS Cell Culture and Transfection
Human embryonic kidney (HEK-293) cells were grown and maintained in Dulbecco's Modified Eagle Medium, supplemented with 10% fetal bovine serum and 1% penicillinstreptomycin (Invitrogen, Paisley, UK). Confluent cells were subcultured every 3-4 days and plated onto 35-mm dishes at low density for electrophysiological experiments. All cells were maintained in an incubator at 37°C and 5% CO 2 .
HEK-293 cells were transfected using the calcium phosphate precipitation method with human SCN5A (adult or neonatal) in pcDNA3.1 vector at 1 µg/dish, along with cDNA for green fluorescent protein at 0.1 µg/dish. 10 Green fluorescent protein was used to identify transfected cells.
Electrophysiology
Currents were recorded from HEK-293 cells transiently expressing aNa V 1.5 or nNa V 1.5 using the whole-cell voltage-clamp technique. Currents were recorded using an Axopatch 200B patch-clamp amplifier, low-pass filtered at 2 KHz, digitized by Digidata 1320A interface, sampled at 4 KHz, and acquired using pClamp8 software (Molecular Devices, San Jose, CA). Pipettes were formed from borosilicate glass capillaries and had resistances between 1.5 and 3 MΩ when filled with intracellular solution, containing (in mM) the following: 130 CsCl, 15 NaCl, 2 MgCl 2 , 10 EGTA, and 10 HEPES. The extracellular solution contained (in mM) the following: 140 NaCl, 4.7 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 10 glucose, and 10 HEPES. Series resistance compensation was ≥85%, to minimize voltage errors, which were only accepted if <4 mV, taking into consideration the peak current and the access resistance. A holding potential of -80 mV was used in all protocols unless stated otherwise. All solutions were bath applied, and recordings were made under continuous perfusion of bath solutions at room temperature. No corrections were made for liquid junction potential compensation.
Data Analysis
Current amplitudes were measured using pClamp10 (Molecular Devices). Plots of the voltage dependence of activation were derived from current-voltage relationships. The driving force at each holding potential (up to +20 mV) was determined from the theoretical Na + equilibrium potential, to calculate Na + conductance. Conductances were normalized to the respective peak values in each cell. For the voltage dependence of inactivation, the amplitude of the available current was normalized to peak amplitude values for each cell. Activation and inactivation data were fitted with Boltzmann functions, as described previously. 10 Concentration-response data were fitted with a logistic function. 10 Average parameters were determined from fits to data acquired from individual cells. For recovery from inactivation, currents were normalized to peak values and data were fitted using the sum of 2 exponential functions. Time constants were determined from data obtained from individual cells. Weighted time constants (τ w ) were calculated as follows:
where τ f and τ s are the fast and slow time constants, respectively, and A f and A s are the relative amplitudes of the fast and slow components, respectively. Nonlinear regression fitting and graphing were performed using GraphPad Prism software (La Jolla, CA).
Statistical Analysis
All data are presented as mean (SD). Comparisons of current density values, V½ activation, V½ inactivation, and their slope values before and after LA application were performed using the paired t test (2 tailed). Pairwise comparisons between low and high concentrations of LA at hyperpolarized potentials were performed using the 2 sample t test (2 tailed). Comparisons involving the extent of inhibition by LAs at different holding potentials (−80, −90, and −120 mV) were performed using a 1-way analysis of variance (ANOVA). Subsequent multiple pairwise comparisons between each holding potential were corrected using the Tukey method. All comparisons interrogating the influence of both LA and splice variants were performed using a 2-way ANOVA. In all cases, an interaction between the 2 factors (LA and splice variant) was also tested. Statistically significant influences of either factor or a significant interaction between the factors were further analyzed with pairwise The number of biological replicates for this study were chosen on the basis of our previous study with similar in vitro experiments 10 enabling detection of differences ≥10% in our parameters of interest. We considered differences <10% unlikely to be physiologically meaningful.
RESULTS

Concentration Dependence of Lidocaine and
Levobupivacaine Inhibition of Na V 1.5 Variants
We established the potency of lidocaine and levobupivacaine as inhibitors of aNa V 1.5 and nNa V 1.5 ( Figure 1A , B). Peak current amplitudes recorded in the presence of LAs were normalized to control and plotted as a concentrationresponse relationship ( Figure 1C, D) . Supplemental Digital Content, Table 1 , http://links.lww.com/AA/C481, contains the fit parameters. We used a 2-way ANOVA to analyze differences in mean IC 50 and Hill coefficient values between the LAs and splice variants. There was no significant influence of splice variant on IC 50 (F 1,20 = 1.8; P = .2). However, the LAs did have different potencies (F 1,20 = 41; P < .0001). A simple pairwise comparison with a Bonferroni correction revealed levobupivacaine to be more potent than lidocaine at either aNa V 1.5 or nNa V 1.5 (P < .0001 and P = .001, respectively; Supplemental Digital Content, Table 1 , http://links. lww.com/AA/C481). In general, levobupivacaine was ~10-fold more potent than lidocaine. There were no differences in the Hill coefficients between either LA or splice variants (F 1,20 = 0.08; P = .78; F 1,20 = 1.5; P = .24, respectively, 2-way ANOVA). In subsequent experiments, we used 10 µM lidocaine and 1 µM levobupivacaine (approximately equally effective concentrations; Figure 1 ).
Lidocaine and Levobupivacaine Affect the Voltage Dependence of Na V 1.5 Activation Table 2 , http://links.lww. com/AA/C481). In light of this differential effect of levobupivacaine, we compared the change in the V½ activation (Δ V½) using a 2-way ANOVA ( Figure 2H ). We found a significant effect of the variant on Δ V½ (F 1,33 = 10; P = .003), but no significant influence of the LA used (F 1,33 = 0.10; P = .32), and also no significant interaction between the splice variant and LA used (F 1,33 = 2.7; P = .11). A pairwise comparison using a Bonferroni correction revealed that levobupivacaine caused a significantly larger shift in V½ of activation in aNa V 1.5 than nNa V 1.5 ( Figure 2H ). The LAs altered the shape of the activation curves, both significantly increased the slope parameters for both aNa V 1.5 and nNa V 1.5 (versus control; Supplemental Digital Content, Table 2 , http://links.lww.com/AA/C481). We analyzed the extent of change (∆ slope) with a 2-way ANOVA ( Figure 2I ). We found no significant influence of either LA (F 1,33 = 1.5; P = .23) or splice variant (F 1,33 = 1.8; P = . 19) , suggesting that the degree of change in the slope parameter is similar ( Figure 2I ).
Lidocaine and Levobupivacaine Show a Preference for the Inactivated State of Both Na V 1.5 Splice Variants
We examined the influence of lidocaine (10 µM) and levobupivacaine (1 µM) on inactivation of currents. We applied 100 milliseconds prepulses from −140 to −10 mV, followed by an activating step to 0 mV to examine the proportion of channels available for activation. The plots of voltage dependence of inactivation and the associated Boltzmann fits are shown in Figure 3A -D, with fitting parameters summarized in Supplemental Digital Content, Figure 3E ). Both LAs significantly increased the slope for nNa V 1.5 (paired t test; Supplemental Digital Content, Table  2 , http://links.lww.com/AA/C481). For aNa V 1.5, only lidocaine significantly increased the slope (Supplemental Digital Content, Table 2 , http://links.lww.com/AA/C481). The maximum available current at −140 mV appears less depressed for aNa V 1.5 in the presence of lidocaine ( Figure 3A) . Indeed, a comparison of the maximum inhibition (from the Boltzmann fits) revealed a significant (paired t test) reduction for levobupivacaine on both variants and lidocaine on only nNa V 1.5 (Supplemental Digital Content, Table 2 , http://links.lww.com/AA/C481). We analyzed the maximum inhibition using a 2-way ANOVA ( Figure 3F ). We found no significant influence of either LA (F 1,33 = 0.11; P = .75) or splice variant (F 1,33 = 0.26; P = .62), but a significant interaction between the 2 (F 1,33 = 8.7; P = .006) was found. A simple effects paired comparison with a Bonferroni correction revealed that levobupivacaine caused a greater reduction in the maximal available current than lidocaine in aNa V 1.5 (P = .03), but not nNa V 1.5. Also, lidocaine caused a greater inhibition of the maximal available current mediated by nNa V 1.5 than that mediated by aNa V 1.5 (P = .009; Figure 3F ).
Inhibition by Lidocaine and Levobupivacaine Is Dependent on the Inactivated State
Low concentrations of lidocaine or levobupivacaine shifted the V½ of inactivation to more hyperpolarized potentials, consistent with a potent action of these LAs to stabilize the inactivated state (Figure 3) . These experiments were performed with a holding potential of −80 mV at which there was approximately 40% steady-state inactivation. To test the hypothesis that inhibition by LAs requires inactivation, we investigated tonic inhibition at −80, −90, and −120 mV. Currents were first recorded in control conditions. Stimulation was subsequently stopped and cells were exposed to lidocaine (10 µM) or levobupivacaine (1 µM) for 120 seconds. The extent of reduction of the first current after LA exposure revealed the magnitude of tonic inhibition. Representative examples of tonic inhibition by lidocaine for nNa V Figure 4B , C). There were significant differences (1-way ANOVA) in the inhibition at the 3 holding potentials for aNa V 1.5 (F 2,12 = 17; P < .0001 for lidocaine, F 2,9 = 26; P < .0001 for levobupivacaine; Figure 4B ) and nNa V 1.5 (F 2,8 = 23; P = .001 for lidocaine, F 2,9 = 15; P = .001 for levobupivacaine; Figure 4C ). Using a post hoc Tukey's comparison, we found a significant reduction in tonic inhibition for aNa V 1.5 between −80 and −90 mV (P = .001 for lidocaine; P = .001 for levobupivacaine) and between −80 and −120 mV (P = .001 for lidocaine; P < .0001 for levobupivacaine). A similar relationship was observed for nNa V 1.5 (−80 vs −90 mV, P = .001 for lidocaine; P = .001 for levobupivacaine; −80 vs −120 mV, P = .01 for lidocaine; P = .001 for levobupivacaine; Figure 4C ).
Inhibition of Resting Na V 1.5 by Lidocaine and Levobupivacaine Occurs at High Concentrations
Neither lidocaine (10 µM) nor levobupivacaine (1 µM) had a significant impact on Na V 1.5 at potentials more hyperpolarized than −90 mV in cells that were held at −120 mV between sweeps ( Figure 5A-D) . The best-fit parameters are summarized in Supplemental Digital Content, Table  3 , http://links.lww.com/AA/C481. For both variants at a holding potential of −120 mV, we observed a small shift in V½ of inactivation at low concentrations of either LA, with no other significant changes to the fitting parameters (Supplemental Digital Content, Table 3 , http://links.lww. com/AA/C481). Most notably, there was no depression of the maximum available current, by contrast to the inhibition observed at −80 mV ( Figure 3 ). The efficacy of the LAs to depress the maximum amplitude was restored (paired t test versus control; Supplemental Digital Content, Table 3 , http://links.lww.com/AA/C481) at hyperpolarized potentials by a higher concentration of either lidocaine (300 µM) or levobupivacaine (100 µM). There were no significant differences (2-way ANOVA) in the extent of this inhibition by either LA or splice variant ( Figure 5E ). The ∆ V½ was generally similar to that of lower concentrations of LAs, except in the case of lidocaine (300 µM) on aNa V 1.5, which caused a greater ∆ V½ than in the presence of 10 µM lidocaine (P = .009; t test; data not shown). There was a significant influence of splice variant on ∆ V½ (2-way ANOVA, F 1,13 = 12; P = .004; Figure 5F ). Paired comparisons using a Bonferroni correction revealed significant differences between aNa V 1.5 and nNa V 1.5 in the presence of either lidocaine (P = .02) or levobupivacaine (P = .048; Figure 5F ). Lidocaine significantly changed the slope of the Boltzmann fit, while levobupivacaine did not (paired t test versus control; Supplemental Digital Content, Table 3 , http://links.lww.com/AA/C481).
We extended our investigation to evaluate tonic block of aNa V 1.5 at a holding potential of −120 mV. We compared the extent of tonic block in the presence of low concentrations of either LA (data from Figure 4 ) with that observed in the presence of high concentrations of lidocaine (300 µM; Figure 5G ) and levobupivacaine (100 µM; Figure 5H ). Using a t test, we found a significant increase in tonic inhibition in the presence of the higher concentration of either lidocaine (P < .0001; Figure 5G ) or levobupivacaine (P < .0001; Figure 5H ). Taken together, our data indicate that the inactivated state is not required for inhibition of Na V 1.5 currents by high concentrations of LAs, but is necessary for inhibition at lower concentrations.
Low Concentrations of Lidocaine and
Levobupivacaine Cause Differential Slowing of Na V 1.5 Recovery From Inactivation Finally, we investigated the rate of recovery from inactivation in the presence and absence of lidocaine (10 µM) or levobupivacaine (1 µM). After inhibition had plateaued at −80 mV, the holding potential was stepped to −120 mV for 2 milliseconds-30 seconds, to sample recovery from inactivation ( Figure 6A, inset) . The recovery data for the aNa V 1.5 ( Figure 6A ) and nNa V 1.5 ( Figure 6B ) were fitted with double exponential functions. The best-fit parameters are summarized in Supplemental Digital Content, Table  4 , http://links.lww.com/AA/C481 and used to calculate τ w values ( Figure 6C ). The identity of the splice variant did not influence τ w (2-way ANOVA, F 1,28 = 0.48; P = .50). However, the identity of the LA did influence τ w (F 2,28 = 11.8; P < .0001). In the absence of LA, the mean τ w values for recovery from inactivation did not differ. However, the τ w of recovery in the presence of levobupivacaine was significantly slower than controls for both splice variants (P = .01 for aNa V 1.5; P = .003 for nNa V 1.5; post hoc Bonferroni correction; Figure 6C ; Supplemental Digital Content, Table 4 , http://links.lww.com/AA/C481). The τ w for lidocaine did not significantly differ from controls. The slowed recovery from inactivation in the presence of levobupivacaine can be mainly attributed to an increase in the slow time constant (Supplemental Digital Content, Table 4 , http://links.lww. com/AA/C481). An increase in the slow time constant was not seen in the presence of lidocaine. Taken together, our data indicate that low concentrations of LA alter the rate of recovery from inactivation, with levobupivacaine having a larger impact than lidocaine.
DISCUSSION
Lidocaine and levobupivacaine cause potent inhibition of nNa V 1.5 and aNa V 1.5, an effect that was lost at holding potentials below −80 mV. Inhibition was half-maximal in the low micromolar range, which can be safely achieved in the blood. 15, 16 There was no difference in the potency of block of either variant by the LAs, suggesting that the presence of neonatal Na V 1.5 on breast 17 and colon cancer cells is unlikely to provide a strategy for selectively targeting their inhibition, consistent with our previous findings with ropivacaine. 10 Human cardiac myocytes have a membrane potential of approximately −90 mV, 18 at which high micromolar concentrations of lidocaine or levobupivacaine were required to inhibit either Na V 1.5 variant. The enhanced sensitivity to LA block, in cells with membrane potentials more depolarized than −90 mV, coincides with the appearance of prevalent inactivation, in agreement with previous observations with lidocaine, bupivacaine (the racemic mixture of the S-and R-enantiomers) and ropivacaine. 3, 10, 19, 20 Indeed, the large increase in native cardiac VASC affinity for lidocaine caused by inactivation has been well established. 21, 22 Importantly, Table  3 , http://links.lww.com/AA/C481. Mean ∆ V½ of activation (E) and extent of inhibition of maximum available current (G). The data were analyzed using a 2-way analysis of variance with LA and splice variant as the factors. Asterisk indicates statistically significant difference following the Bonferroni correction. Statistical parameters are given in the text. Graphs show mean % inhibition of lidocaine (G) and levobupivacaine (H) after 2-min exposure to low (10 µM for lidocaine, 1 µM for levobupivacaine) and high concentrations (300 µM for lidocaine, 100 µM for levobupivacaine) without stimulation, with the holding membrane potential at −120 mV. The low concentration data is reproduced here from Figure 4B , C for comparison. Asterisk indicates a statistically significant (t test) increase in tonic inhibition with the higher concentration of LA.
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Local Anesthetic Inhibition of Na V 1.5 Variants the inactivated state of Na V 1.5 predominates at the resting membrane potential of colon cancer cells (approximately −40 mV). 10, 23 Consistent with our previous observation with ropivacaine, 10 both LAs shifted the peak window current (representing the membrane potential of peak steady-state current) to potentials below −40 mV (Supplemental Digital Content, Figure 1 , http://links.lww.com/AA/C481). Therefore, inactivation state-dependent high potency block provides a potential strategy for targeting Na V 1.5 on cancer cells while sparing cardiac myocytes, in which VASCs recover from inactivation during repolarization even at high stimulation frequencies. 18 Our findings support previous observations of large state-dependent block by LAs which overshadows any VASC subtype specificity of these and related drugs. 24, 25 There were differences observed for both Na V 1.5 variants with regard to their responses to LAs. Levobupivacaine caused a greater depolarizing shift in the V½ of activation of aNa V 1.5 compared to nNa V 1.5. In this regard, it is relevant that the high-affinity block of Na V 1.5 by LAs has been termed voltage-sensor block due to a proposed stabilization of S4 voltage sensors in domains III and IV. 2 The nNa V 1.5 variant has several alternative amino acids in the S4 of domain I, including a lysine in place of the aspartate at the equivalent position in aNa V 1.5. This substitution leads to a depolarizing shift in the V½ of activation. 10, 17 This lysine may stabilize the voltage sensors in a manner similar to that of LA stabilization in aNa V 1.5, thereby masking this effect in nNa V 1.5.
There are developmental changes in block by lidocaine on neonatal and adult rat cardiac myocytes. Native neonatal VASCs are more sensitive to inhibition by lidocaine. 26 However, this developmental effect appears to be species specific. 27 Our observations for nNa V 1.5 and aNa V 1.5 suggest that any developmental changes in lidocaine sensitivity of human myocardial VASCs is unlikely to be explained by alternative Na V 1.5 splicing.
Molecules that bind to the LA site are thought to inhibit function through a similar mechanism.
1,28 Structural modeling suggests that these drugs inhibit current through steric interactions with the Na + binding sites close to the LA binding site. 29 As expected, in our study, inhibition by the 2 LAs was similar; however, reversal of Na V 1.5 inactivationdependent inhibition by levobupivacaine was slower than that of lidocaine. In this paradigm, reversal of inhibition from slow inactivation likely represents a combination of recovery from slow inactivation and LA unbinding. 21, 30, 31 In the absence of LAs, both variants exhibited similar rates and contributions of fast and slow components of recovery from inactivation. Levobupivacaine reduced the slow rate of recovery from inactivation. Lidocaine, by contrast, did not affect either the fast or slow rates but did somewhat increase the contribution of the slow component. The slower rate of slow recovery from inactivation in the presence of levobupivacaine could be caused by slow unbinding. Levobupivacaine is more hydrophobic than lidocaine due to its propylpiperidine group, and likely contributes to its higher potency. Additionally, highly hydrophobic inhibitors may be able to enter and exit the binding site via lipid fenestrations within the membrane-spanning domains of Table 4 , http://links.lww.com/AA/C481. From these parameters, the weighted time constant (τ w ) was calculated. Mean τ w are plotted in C. We compared mean τ w using a 2-way analysis of variance across treatment (control, lidocaine, levobupivacaine) and splice variant (details of statistics in the text). Asterisks indicate a statistically significant change in τ w versus control following the Bonferroni correction.
VASCs and may remain trapped within hydrophobic pockets. 28, 32 This may result in a longer lasting reduction in Na + entry by levobupivacaine than lidocaine. Previous studies with bupivacaine on guinea-pig heart showed that bupivacaine fails to unbind in diastole and causes cardiotoxicity. 33 It is unclear to what extent VASC inhibition is involved in the cardiotoxic effects of LAs, although slowed recovery from inactivation is likely to be a contributing factor. 34 The S-enantiomer, levobupivacaine, appears less toxic than the R-enantiomer, according to preclinical data, and may therefore cause less slowing of recovery from inactivation. 35 However, our results demonstrate that levobupivacaine causes a greater slowing of recovery of Na V 1.5 inactivation than lidocaine and this may contribute to its cardiotoxicity.
In this study, we used recombinant Na V 1.5 isoforms, which avoids confounding influences of multiple VASCs and simplifies interpretation. However, in cardiac myocytes and cancer cells, additional factors may influence the function of VASC and/or the actions of LAs.
The findings from this study will inform future in vitro investigations into the effectiveness of LAs in inhibiting colorectal cancer cell invasion, for instance, in Matrigel invasion assays. Furthermore, there is considerable interest in the potential of LAs to reduce recurrence or metastases after surgical tumor excision. In light of the direct inhibitory effects on metastatic cancer cell invasion, it might be advantageous to administer LAs intravenously or directly onto tumors before excision. 10 Indeed, the activity of Na V 1.5 influences expression of multiple genes associated with the metastatic potential of colon cancer cells, and blockade by lidocaine, and the associated reduction in Na + entry, reduces the expression of these genes. 9, 11 However, in vivo, LAs are mostly bound to serum proteins and this limits the free concentration available to inhibit Na V 1.5. Nevertheless, because low concentrations of lidocaine and levobupivacaine selectively interact with inactivated Na V 1.5, our study can inform the selection of an appropriate dose which maximizes beneficial effects on cancer progression, while minimizing the likelihood of cardiac toxicity. E 
